Abiomed Reports Updated USpella Results at TCT 2010

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced updated clinical data from USpella, a U.S. multicenter, observational registry of Impella 2.5® patients.